World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
131
Citations
92187
World Ranking
2346
National Ranking
1322

Kenneth R. Hess publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Kenneth R. Hess sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 650 publications — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Kenneth R. Hess D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Kenneth R. Hess sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 131 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2017 - Fellow of the American Statistical Association (ASA)

Overview

Kenneth R. Hess was affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, and Molecular Biology.

The primary topics addressed in their work included Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Cancer Survivorship and Care, Cancer Treatment and Pharmacology, and Cancer Genomics and Diagnostics.

They published research in several prominent venues, frequently contributing to these journals:

  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • Journal of Clinical Oncology
  • British Journal of Cancer
  • ESMO Open

Their recent papers included:

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, 2023, Journal of Clinical Oncology
  • Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial, 2020, Journal for ImmunoTherapy of Cancer
  • Phase 2 study of pembrolizumab in patients with advanced rare cancers, 2020, Journal for ImmunoTherapy of Cancer
  • Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials, 2020, British Journal of Cancer
  • Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC, 2020, Journal of Thoracic Oncology

The scientist collaborated frequently with peers including Bora Lim, Vicente Valero, Naoto T. Ueno, David S. Hong, and Debu Tripathy.

In recognition of their professional contributions, Kenneth R. Hess was awarded the title of Fellow of the American Statistical Association (ASA) in 2017.

Best Publications

  • AJCC Cancer Staging Manual

    Mahul B. Amin;Stephen B. Edge;Frederick L. Greene;David R. Byrd

  • A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

    Michel Lacroix;Dima Abi-Said;Daryl R. Fourney;Ziya L. Gokaslan

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

    Eric L Chang;Jeffrey S Wefel;Kenneth R Hess;Pamela K Allen

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases

    Eddie K. Abdalla;Jean-Nicolas Vauthey;Lee M. Ellis;Vickie Ellis

  • Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

    Jeffrey E. Gershenwald;Richard A. Scolyer;Kenneth R. Hess;Vernon K. Sondak

  • Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.

    Michele Ceccarelli;Floris P Barthel;Tathiane M Malta;Thais S Sabedot

  • Experience with 1509 patients undergoing thoracoabdominal aortic operations

    Lars G. Svensson;E.Stanley Crawford;Kenneth R. Hess;Joseph S. Coselli

  • The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

    Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne

  • Thoracoabdominal aortic aneurysms: Preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients

    E. Stanley Crawford;John L. Crawford;Hazim J. Safi;Joseph S. Coselli

  • Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

    Eric T. Wong;Kenneth R. Hess;Mary Jo Gleason;Kurt A. Jaeckle

  • Metastatic patterns in adenocarcinoma

    Kenneth R. Hess;Gauri R. Varadhachary;Sarah H. Taylor;Wei Wei

  • Deep hypothermia with circulatory arrest. Determinants of stroke and early mortality in 656 patients

    L. G. Svensson;E. S. Crawford;K. R. Hess;J. S. Coselli

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

    James C. Yao;Alexandria T. Phan;David Z. Chang;Robert A. Wolff

  • Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors

    Raymond Sawaya;Maarouf Hammoud;Derek Schoppa;Kenneth R. Hess

  • Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial

    Anita Mahajan;Salmaan Ahmed;Mary Frances McAleer;Jeffrey S Weinberg

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

    M. Ayers;W.F. Symmans;J. Stec;A.I. Damokosh

Frequent Co-Authors

David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Apostolia Maria Tsimberidou
Apostolia Maria Tsimberidou The University of Texas MD Anderson Cancer Center
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
W. K. Alfred Yung
W. K. Alfred Yung The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University
James L. Abbruzzese
James L. Abbruzzese Duke University
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare but seeking flexible or alternative pathways? There are now a variety of online programs available for those looking to advance or start their medical careers without sacrificing work or family commitments. For registered nurses, rn to bsn programs no clinicals offer a convenient way to upgrade qualifications through coursework alone—no in-person clinicals required.

If you are hoping to achieve a Doctor of Nursing Practice, you may consider the dnp online programs that can be completed in less time due to their accelerated formats. For added flexibility, some of the online dnp programs without clinicals let working professionals earn advanced degrees without traditional hands-on requirements.

For those just beginning in nursing, lpn fast track program options can provide a quick start to a rewarding career. These streamlined courses facilitate faster entry into the workforce, making them a popular choice for career changers and recent graduates alike.

Best Scientists Citing Kenneth R. Hess

Recently Published Articles